Updates are available Correction dated 2021-01-20
Click to view Correction: https://doi.org/10.1038/s41467-021-20978-y
-
Authors
Landau, Heather J.
Yellapantula, Venkata
Diamond, Benjamin T.
Rustad, Even H. https://orcid.org/0000-0002-9320-4963
Maclachlan, Kylee H.
Gundem, Gunes
Medina-Martinez, Juan
Ossa, Juan Arango
Levine, Max F. https://orcid.org/0000-0001-5156-9086
Zhou, Yangyu
Kappagantula, Rajya
Baez, Priscilla
Attiyeh, Marc https://orcid.org/0000-0002-9949-1449
Makohon-Moore, Alvin
Zhang, Lance
Boyle, Eileen M.
Ashby, Cody https://orcid.org/0000-0002-9361-0283
Blaney, Patrick
Patel, Minal
Zhang, Yanming
Dogan, Ahmet https://orcid.org/0000-0001-6576-5256
Chung, David J.
Giralt, Sergio
Lahoud, Oscar B.
Peled, Jonathan U.
Scordo, Michael
Shah, Gunjan
Hassoun, Hani
Korde, Neha S.
Lesokhin, Alexander M.
Lu, Sydney
Mailankody, Sham
Shah, Urvi https://orcid.org/0000-0001-8419-1091
Smith, Eric
Hultcrantz, Malin L. https://orcid.org/0000-0002-9045-6495
Ulaner, Gary A.
van Rhee, Frits
Morgan, Gareth J.
Landgren, Ola https://orcid.org/0000-0001-6485-4839
Papaemmanuil, Elli https://orcid.org/0000-0003-1709-8983
Iacobuzio-Donahue, Christine https://orcid.org/0000-0002-4672-3023
Maura, Francesco https://orcid.org/0000-0002-5017-1620
- License Information
-
More Information
Article History
Received: 4 March 2020
Accepted: 2 July 2020
First Online: 17 July 2020
Change Date: 20 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-20978-y.
Competing interests
: J.U.P. reports research funding, intellectual property fees, and travel reimbursement from Seres Therapeutics and consulting fees from DaVolterra. M.S. has served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation. He has received research funding from Angiocrine Bioscience, Inc. He has served on an ad hoc advisory board for Kite – A Gilead Company. H.J.L. has received research support for clinical trials from Takeda. She served on the advisory boards of Takeda, Celgene, Janssen, Sanofi, Caelum Biosciences and has been a consultant for Karyopharm and Pfizer. Other authors declare no competing interests.
